Valproate therapy and nonalcoholic fatty liver disease.
Nonalcoholic fatty liver disease was defined recently as another symptom of insulin resistance. Continuous therapy with valproate can result in increased body weight and insulin resistance, but no data are yet available on a possible relationship between valproate and nonalcoholic fatty liver disease. We here demonstrate in abdominal ultrasound investigations that characteristics of fatty liver disease were present in 61% of valproate-treated patients as compared with 23% receiving carbamazepine therapy.
Luef
Gerhard J
GJ
Department of Neurology, Innsbruck University Hospital, Innsbruck, Austria. gerhard.luef@uibk.ac.at
Waldmann
Markus
M
Sturm
Wolfgang
W
Naser
Anis
A
Trinka
Eugen
E
Unterberger
Iris
I
Bauer
Gerhard
G
Lechleitner
Monika
M
D000293:Adolescent; D000328:Adult; D002220:Carbamazepine / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004827:Epilepsy / Q000188:drug therapy; D005234:Fatty Liver / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D014463:Ultrasonography; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
D002220:Carbamazepine; D014635:Valproic Acid